Immunization

EQS-News: GEA’s factory in Elsdorf sets new standards in pharmaceutical production

Retrieved on: 
Wednesday, April 10, 2024
Electricity, EUR, Biodiversity, Growth, Disease, GEA, Food, Immunization, Fruit, Vaccine, Workplace

Groundbreaking ceremony for GEA’s second “Factory of the Future” covering an area of over 40,000 m2 in Elsdorf, Germany

Key Points: 
  • Groundbreaking ceremony for GEA’s second “Factory of the Future” covering an area of over 40,000 m2 in Elsdorf, Germany
    Düsseldorf, March 22, 2024 – Construction of GEA’s new pharmaceutical technology center in Elsdorf, Germany, begins today – setting new industry benchmarks.
  • With people increasingly aware of the major role immunization plays in preventing disease, the market for vaccines is growing rapidly worldwide.
  • At Elsdorf, state-of-the-art processes and working methods as well as the associated digitalization are the main focus alongside sustainable construction.
  • This is why the new pharmaceutical technology center is going to be built according to the highest sustainability standards.

Dr. Chi Li Joins Curevo Vaccine as Chief Regulatory Officer

Retrieved on: 
Monday, April 8, 2024
Shingles, Editas Medicine, Regulatory affairs, Bristol Myers Squibb, Doctor of Philosophy, MBA, Rutgers University, Immunization, Johnson & Johnson, Allergan, RAC, Vaccine, Purdue University, Pharmaceutical industry

SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus vaccines with improved tolerability and accessibility, today announced Dr. Chi Li is joining as the company’s Chief Regulatory Officer responsible for the global regulatory strategy for amezosvatein.

Key Points: 
  • SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus vaccines with improved tolerability and accessibility, today announced Dr. Chi Li is joining as the company’s Chief Regulatory Officer responsible for the global regulatory strategy for amezosvatein.
  • “We are thrilled to have Dr. Li join the Curevo team and build upon the regulatory progress made thus far,” stated George Simeon, Curevo’s Chief Executive Officer.” Dr. Li will play a key role in finalizing our global regulatory strategy and harmonizing our approach to key entry markets in Europe, the USA, China, Japan, and other important markets for our shingles and varicella vaccine.”
    Dr. Li’s impressive 20+ year career in regulatory affairs features multiple regulatory successes globally.
  • “I’m genuinely impressed at what the Curevo team has accomplished to date and am excited to join such a dynamic group,” said Dr. Li.
  • Previously, Dr. Li served as Vice President, Regulatory Affairs at both Allergan and Bayer.

Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting

Retrieved on: 
Friday, April 5, 2024
CD4, CD8, AMP, Development, Antigen, Immunotherapy, Colorectal cancer, Memory, Patient, Lung, GM-CSF, Biomarker, DNA, Epitope, Cancer, Granzyme B, BRAF, Lymph, IL2, Circulating tumor DNA, Phenotype, Neoplasm, Research and development, Immunization, Therapy, Vaccination, CRC, V600E, Immune system, Melanoma, Granzyme, Phase 1, Amphetamine, Nature Medicine, Annual general meeting, Vaccine

Preclinical data on vaccine candidates, ELI-007 and ELI-008, investigational peptide vaccines targeting BRAF and p53-driven cancers, respectively, will also be shared.

Key Points: 
  • Preclinical data on vaccine candidates, ELI-007 and ELI-008, investigational peptide vaccines targeting BRAF and p53-driven cancers, respectively, will also be shared.
  • A majority of patients who received the booster immunizations maintained or increased mKRAS-specific T cell responses relative to baseline.
  • The mKRAS-specific CD4 and CD8 T cells generated by ELI-002 exhibited increased cytotoxic function and development of favorable memory phenotype.
  • "Earlier data published in Nature Medicine demonstrate that our off-the-shelf lymph node-targeted cancer vaccine candidate, ELI-002, induces memory T cell responses.

Unity Consortium Marks Adolescent Immunization Action Week (AIAW) with activities to help Parents and Adolescents get up to date on Recommended Vaccines

Retrieved on: 
Thursday, March 28, 2024
Health, Organization, TASK, Doctor of Philosophy, Assistant, Caregiver, Parent, Pharmacy, Comcast, Adolescence, Vaccine hesitancy, Social media, Research, Internet, MD, Trust, Immunization, MPH, TelevisaUnivision, Clinton Foundation, Vaccine, PSA, Vaccination

AIAW is a national movement aimed at parents, adolescents and healthcare providers to ensure adolescents are up to date on well visits and recommended vaccines.

Key Points: 
  • AIAW is a national movement aimed at parents, adolescents and healthcare providers to ensure adolescents are up to date on well visits and recommended vaccines.
  • Across the nation, organizations interested in the health of adolescents are participating in AIAW to help protect adolescents from vaccine-preventable illnesses.
  • To address these challenges, Unity wants parents to help adolescents and young adults stay healthy by Staying on TASK with vaccines.
  • As AIAW kicks off, Unity offers activities and resources to support Adolescent Immunization Action Week efforts, including:
    A graphic and video animation of Staying on TASK.

NFID Announces 2024 Recipients of Prestigious Awards

Retrieved on: 
Tuesday, April 9, 2024
RN, Maxwell Finland Award, COVAX, Health equity, HIV, Biomedical Research, Health, Patient, Epidemic, Infection, Rockefeller Foundation, Vaccine, Ageing, AIDS, International, Education, Policy, Master of Science, Woman, Gavi, World Health Organization, Immunization, Safety, Disease, Global health, Public, Research, Death, Mentorship, NFID, MPH, National Academy of Medicine, CPNP, COVID-19, IAVI, National academy, Developed country

BETHESDA, Md., April 9, 2024 /PRNewswire/ -- The National Foundation for Infectious Diseases (NFID) has announced the 2024 recipients of the prestigious NFID awards honoring outstanding individuals who have made significant and lasting contributions to public health through leadership, scientific achievement, philanthropy, and policy work. The following awards will be presented at the 2024 NFID Awards Gala in Washington, DC in September 2024:

Key Points: 
  • BETHESDA, Md., April 9, 2024 /PRNewswire/ -- The National Foundation for Infectious Diseases (NFID) has announced the 2024 recipients of the prestigious NFID awards honoring outstanding individuals who have made significant and lasting contributions to public health through leadership, scientific achievement, philanthropy, and policy work.
  • The following awards will be presented at the 2024 NFID Awards Gala in Washington, DC in September 2024:
    Seth F. Berkley, MD, of the Pandemic Center of Brown University, will receive the 2024 Jimmy and Rosalynn Carter Humanitarian Award in recognition of his work as an innovative entrepreneur, a pioneer in global health, and a champion of equitable access to vaccines.
  • The awards will be presented at the 2024 NFID Awards Gala and Silent Auction, a black-tie fundraising event scheduled for September 19, 2024, in Washington, DC.
  • All contributions support the NFID mission to educate the public and healthcare professionals on the prevention and treatment of infectious diseases.

Viral Vector and Plasmid DNA Technologies and Global Market Analysis - A USD 7.1 Billion Market by 2028, Expansion of Biotechnological Applications Fuels Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 2, 2024
Cardiology, Biotechnology, Health, Pharmaceutical, Oncology, Health Technology, Other Science, Research, Infectious Diseases, Genetics, Science, AAV, Transfection, QC, HSV, Acute lymphoblastic leukemia, Growth, Prevalence, Cell, Incidence, ALL, Tissue, DNA, Mortality, Virus, Cancer, Human, Infection, World Health Organization, Neoplasm, Immunization, Safety, WHO, Therapy, Inosine pranobex, USD, DSM-IV codes, Tisagenlecleucel, Vaccine

The rising incidence and prevalence rate of cancer is considered a key factor in the growth of the global viral vector and plasmid DNA technologies market.

Key Points: 
  • The rising incidence and prevalence rate of cancer is considered a key factor in the growth of the global viral vector and plasmid DNA technologies market.
  • However, regulatory challenges, vector characterization, and QC testing, and manufacturing challenges have restrained growth in the global viral vector and plasmid DNA technologies market.
  • The global viral vector and plasmid DNA technologies market is segmented based on the product, application, and end-user.
  • Based on the product, the global viral vector and plasmid DNA technologies market further is analyzed into plasmid DNA and viral vectors.

ReportLinker Reveals Key Insights About Players and Coverage in Latest Combination Vaccine Market Analysis

Retrieved on: 
Tuesday, March 26, 2024
Intelligence, AP, Sanofi, Vaccine, NLP, Growth, Natural language processing, Immunization, Interview, Vaccination

This recent comprehensive study analyzes global volumes and utilization trends for aP combination vaccines, including hexavalent and pentavalent vaccines, and confirms Sanofi's leadership in the global pediatric combination vaccine market.

Key Points: 
  • This recent comprehensive study analyzes global volumes and utilization trends for aP combination vaccines, including hexavalent and pentavalent vaccines, and confirms Sanofi's leadership in the global pediatric combination vaccine market.
  • The study reveals a notable rebound in immunization rates, with DTP3 coverage rising to 84% in 2022, and delves into global trends in the utilization of aP-based hexavalent and pentavalent combination vaccines, highlighting significant market dynamics and leadership.
  • Geographically, Europe is noted for its significant share of the aP-based combination vaccines market, especially in the hexavalent and pentavalent categories.
  • This regional analysis, along with a detailed breakdown of vaccine usage in top countries, offers a clear view of global vaccination strategies and their impact.

ReportLinker Reveals Key Insights About Players and Coverage in Latest Combination Vaccine Market Analysis

Retrieved on: 
Tuesday, March 26, 2024
Intelligence, AP, Sanofi, Vaccine, NLP, Growth, Natural language processing, Immunization, Interview, Vaccination

This recent comprehensive study analyzes global volumes and utilization trends for aP combination vaccines, including hexavalent and pentavalent vaccines, and confirms Sanofi's leadership in the global pediatric combination vaccine market.

Key Points: 
  • This recent comprehensive study analyzes global volumes and utilization trends for aP combination vaccines, including hexavalent and pentavalent vaccines, and confirms Sanofi's leadership in the global pediatric combination vaccine market.
  • The study reveals a notable rebound in immunization rates, with DTP3 coverage rising to 84% in 2022, and delves into global trends in the utilization of aP-based hexavalent and pentavalent combination vaccines, highlighting significant market dynamics and leadership.
  • Geographically, Europe is noted for its significant share of the aP-based combination vaccines market, especially in the hexavalent and pentavalent categories.
  • This regional analysis, along with a detailed breakdown of vaccine usage in top countries, offers a clear view of global vaccination strategies and their impact.

Oracle Delivers Foundation for More Intelligent Healthcare

Retrieved on: 
Tuesday, March 12, 2024
Cloud, RN, Health, ROI, Government, Risk management, Intelligence, Diabetes, Patient, Oracle Cloud, Public, DNP, Health information management, OCI, AI, IDC, Overalls, HIMSS, Address, Immunization, Oracle, Breast cancer, CCM, EHR, Medicare, Update, Medical device

AUSTIN, Texas, March 12, 2024 /PRNewswire/ -- Oracle today announced significant enhancements to Oracle Health Data Intelligence, including a new generative AI service to help increase care management efficiency. Oracle Health Data Intelligence, formerly HealtheIntent, is a modular suite of cloud applications, services, and analytics. The suite enables a broad range of healthcare and government stakeholders to use data from across the healthcare ecosystem to help advance patient health, improve care delivery, and drive operational efficiency. Additional new capabilities include system performance improvements, pre-built clinical quality analytics, and automated alerts that can help increase reimbursements and enhance care.

Key Points: 
  • Oracle Health Data Intelligence, formerly HealtheIntent, is a modular suite of cloud applications, services, and analytics.
  • Powered by Oracle Cloud Infrastructure (OCI), Oracle Health Data Intelligence gives customers access to the same mission-critical security, performance, reliability, and other cloud capabilities that Fortune 100 customers in highly regulated industries rely on today.
  • To see Oracle Health in action, please visit us at HIMSS in Orlando March 11 - 15 at booth #2761.
  • Learn how Oracle Health is building an open healthcare platform with intelligent tools for data-driven, human-centric health experiences to connect consumers, providers, payers, public health, and life sciences.

World Vaccine Congress Draws Leaders from Government, Science and Industry

Retrieved on: 
Monday, March 11, 2024
Convention center, Bee, Washington Convention Center, Congress, Walter, Global health, Mayo Clinic, Food and Drug Administration, Cancer, International, Science Advisory Board, World Health Organization, Immunization, Vaccination, Bangladesh Technical Education Board, Vaccine, Food, Pharmaceutical industry

WASHINGTON, March 11, 2024 /PRNewswire/ -- The world's top experts and policymakers, including government leaders, renown researchers and company executives driving vaccine development, will gather to discuss the latest progress in vaccines — from efforts to inoculate bees to a discussion of pathogens that could cause the next pandemic — at the World Vaccine Congress April 1-4.

Key Points: 
  • "We have assembled the world's foremost experts and policymakers in the field of vaccination for the 2024 World Vaccine Congress," said Dr. Gregory A. Poland, Director of Mayo Vaccine Research Group, Mayo Clinic and a member of the Science Advisory Board.
  • "This event represents an unparalleled opportunity for collaboration and innovation and promises to drive meaningful progress in global health.
  • It is a unique and massive forum for discovery and access to leaders across the field."
  • In-depth sessions also cover vaccine supply and logistics, veterinary vaccines, emerging diseases, and vaccine delivery.